PRAME induces apoptosis and inhibits proliferation of leukemic cells in vitro and in vivo

International Journal of Clinical and Experimental Pathology

Volumn 8, Issue 11, 2015, Pages 14549-14555

  Xu, Yu ^a   Yue, Qingcai ^a   Wei, Hong ^b   Pan, Guiju ^a  

^a LINYI PEOPLE'S HOSPITAL   (China)

^b People's Hospital of Zhangqiu   (China)

Author keywords

Acute leukemias; Apoptosis; PRAME; Proliferation

Indexed keywords

PRAME PROTEIN, HUMAN; TUMOR ANTIGEN;

ANIMAL; APOPTOSIS; CELL PROLIFERATION; FLOW CYTOMETRY; GENETIC TRANSFECTION; GENETICS; HUMAN; K-562 CELL LINE; LEUKEMIA; METABOLISM; MOUSE; NUDE MOUSE; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUNEL ASSAY; WESTERN BLOTTING; XENOGRAFT;

ANIMALS; ANTIGENS, NEOPLASM; APOPTOSIS; BLOTTING, WESTERN; CELL PROLIFERATION; FLOW CYTOMETRY; HETEROGRAFTS; HUMANS; IN SITU NICK-END LABELING; K562 CELLS; LEUKEMIA; MICE; MICE, NUDE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSFECTION;

EID: 85013243908     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Ikeda H, Lethe B, Lehmann F, van Baren N, Baurain JF, de Smet C. Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity 1997; 6: 199-208.
2. Kessler JH, Beekman NJ, Bres-Vloemans SA, Verdijk P, van Veelen PA, Kloosterman-Joosten AM. Efficient identification of novel HLAA(*) 0201-presented cytotoxic T lymphocyte epitopes in the widely expressed tumor antigen PRAME by proteasome-mediated digestion analysis. J Exp Med 2001; 193: 73-88.
3. Abdelmalak CA, Yahya RS, Elghannam DM, El-Khadragy AE, Abd El Messih HM. PRAME gene expression in childhood acute lymphoblastic leukemia: impact on prognosis. Clin Lab 2014; 60: 55-61.
4. Ding K, Wang XM, Fu R, Ruan EB, Liu H, Shao ZH. PRAME Gene Expression in Acute Leukemia and Its Clinical Significance. Cancer Biol Med 2012; 9: 73-6.
5. Steinbach D, Viehmann S, Zintl F, Gruhn B. PRAME gene expression in childhood acute lymphoblastic leukemia. Cancer Genet Cytogenet 2002; 138: 89-91.
6. Radich JP, Dai H, Mao M, Oehler V, Schelter J, Druker B. Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci U S A 2006; 103: 2794-2799.
7. Proto-Siqueira R, Figueiredo-Pontes LL, Panepucci RA, Garcia AB, Rizzatti EG, Nascimento FM, Ishikawa HC, Larson RE, Falcão RP, Simpson AJ, Gout I, Filonenko V, Rego EM, Zago MA. PRAME is a membrane and cytoplasmic protein aberrantly expressed in chronic lymphocytic leukemia and mantle cell lymphoma. Leuk Res 2006; 30: 1333-9.
8. Beà S, Salaverria I, Armengol L, Pinyol M, Fernández V, Hartmann EM, Jares P, Amador V, Hernández L, Navarro A, Ott G, Rosenwald A, Estivill X, Campo E. Uniparental disomies, homozygous deletions, amplifications, and target genes in mantle cell lymphoma revealed by integrative high-resolution whole-genome profiling. Blood 2009; 113: 3059-69.
9. Argiris A, Lee SC, Feinstein T, Thomas S, Branstetter BFT, Seethala R. Serum biomarkers as potential predictors of antitumor activity of cetuximab-containing therapy for locally advanced head and neck cancer. Oral Oncol 2011; 47: 961-6.
10. Tanaka N, Wang YH, Shiseki M, Takanashi M, Motoji T. Inhibition of PRAME expression causes cell cycle arrest and apoptosis in leukemic cells. Leuk Res 2011; 35: 1219-25.
11. Paydas S, Tanriverdi K, Yavuz S, Disel U, Baslamisli F, Burgut R. PRAME mRNA levels in cases with acute leukemia: clinical importance and future prospects. Am J Hematol 2005; 79: 257-61.
12. Haqq C, Nosrati M, Sudilovsky D, Crothers J, Khodabakhsh D, Pulliam BL, Federman S, Miller JR, Allen RE, Singer MI, Leong SP, Ljung BM, Sagebiel RW, Kashani-Sabet M. The gene expression signatures of melanoma progression. Proc Natl Acad Sci U S A 2005; 102: 6092-6097
13. van Baren N, Chambost H, Ferrant A, Michaux L, Ikeda H, Millard I, Olive D, Boon T, Coulie PG. PRAME, a gene encoding an antigen recognized on a human melanoma by cytolytic T cells, is expressed in acute leukaemia cells. Br J Haematol 1998; 102: 1376-1379
14. Oehler VG, Guthrie KA, Cummings CL, Sabo K, Wood BL, Gooley T, Yang T, Epping MT, Shou Y, Pogosova-Agadjanyan E. The preferentially expressed antigen in melanoma (PRAME) inhibits myeloid differentiation in normal hematopoietic and leukemic progenitor cells. Blood 2009; 114: 3299-3308.
15. Greiner J, Schmitt M, Li L, Giannopoulos K, Bosch K, Schmitt A, Dohner K, Schlenk RF, Pollack JR, Dohner H, Bullinger L. Expression of tumorassociated antigens in acute myeloid leukemia: Implications for specific immunotherapeutic approaches. Blood 2006; 108: 4109-4117.
16. Doolan P, Clynes M, Kennedy S, Mehta JP, Crown J, O'Driscoll L. Prevalence and prognostic and predictive relevance of PRAME in breast cancer. Breast Cancer Res Treat 2015; 109: 359-365.
17. Epping MT, Hart AA, Glas AM, Krijgsman O, Bernards R. PRAME expression and clinical outcome of breast cancer. Br J Cancer 2008; 99: 398-403.
18. Oberthuer A, Hero B, Spitz R, Berthold F, Fischer M. The tumor-associated antigen PRAME is universally expressed in high-stage neuroblastoma and associated with poor outcome. Clin Cancer Res 2014; 10: 4307-4313.